Stock Research: Steris

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Steris

NYSE:STE IE00BFY8C754
77
  • Value
    67
  • Growth
    39
  • Safety
    Safety
    28
  • Combined
    32
  • Sentiment
    92
  • 360° View
    360° View
    77
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

STERIS Plc provides products and services focused on infection prevention. It operates in Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The company serves healthcare providers worldwide, medical device and pharmaceutical manufacturers globally, and biopharmaceutical and medical device research and manufacturing facilities. In the last fiscal year, the company had a market cap of $22,511 million, profits of $2,403 million, revenue of $5,460 million, and 17,787 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 77 (better than 77% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Steris are very positive. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Steris. The consolidated Sentiment Rank has a good rank of 92, which means that professional investors are more optimistic about the stock than for 92% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 67 or better than 67% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 28, meaning that the share price of Steris is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 39. ...read more

more
Index
Employee Focus EU
D.J. US Medical Equipment
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
28 22 29 43
Growth
39 76 87 67
Safety
Safety
67 26 15 41
Sentiment
92 40 63 87
360° View
360° View
77 28 53 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
83 65 78 90
Opinions Change
88 23 29 50
Pro Holdings
n/a 65 64 86
Market Pulse
13 21 42 24
Sentiment
92 40 63 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
28 22 29 43
Growth
39 76 87 67
Safety Safety
67 26 15 41
Combined
32 23 25 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
36 41 42 36
Price vs. Earnings (P/E)
17 23 28 33
Price vs. Book (P/B)
37 34 34 56
Dividend Yield
42 39 40 42
Value
28 22 29 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
45 45 55 56
Profit Growth
59 36 57 58
Capital Growth
4 89 62 51
Stock Returns
69 60 83 63
Growth
39 76 87 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
68 36 38 52
Refinancing
25 17 33 35
Liquidity
73 42 30 47
Safety Safety
67 26 15 41

Similar Stocks

Discover high‑ranked alternatives to Steris and broaden your portfolio horizons.

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

Schroders

LSE:SDR
Country: United Kingdom
Industry: Asset Management & Custody
Size: Large
Full Stock Analysis

Barratt Developments

LSE:BDEV
Country: United Kingdom
Industry: Homebuilding
Size: Medium
Full Stock Analysis

SSE

LSE:SSE
Country: United Kingdom
Industry: Electric Utilities
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.